Evaluation of an inhibitor of the LRRK 2 gene in Parkinson’s patients. Oral tract. We continue the development of our tractaments that aim to modify the natural history of malaria, slowly progressing.
Trial on LRRK2 mutation in Parkinson’s is about to be completed. Our Trials Unit is the lead international recruiter for this Phase 1 trial. A hope for patients with Parkinson’s and this mutation. keep informed!
Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with Parkinson’s disease with motor fluctuations. NeuroDerm, a subsidiary of Mitsubishi Tanabe Pharma, announced the positive results in January 2023 of this 24h/d subcutaneous infusion of levodopa/carbidopa, with a marked improvement in ON time without bothersome dyskinesias and a reduction in…
The new formulation of inhaled levodopa, Inbrija, has been approved for marketing in Spain. Manufactured by Acorda and distributed by Esteve. Our Clinical Trial Unit evaluated it during 2015 and 2016. It is a new therapy for motor blocks that require an immediate response. Its use at the request of the patient’s needs is noteworthy.
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s disease with motor fluctuations. We have led the clinical trial in Spain with this drug. Our patients are continuing to use it during the open label extension.
An intranasal levodopa has been authorized in the US to treat off blockages, called Inbrija. The European Medicines Agency starts all he procedures in Europe.
Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations. – We are leading the inclusion internationally of a trial with sublingual Apomorphine. Our Unit leads the inclusion of randomized patients comparing sublingual apomorphine versus the classic subcutaneous apomorphine for the indication in blocking off.
Our Unit has achieved to be activated in this outstanding project and so serious pathology. We will participate in its development and also in a phase III.
We appreciate the great effort made by our patients to contribute to the development of this protocol that aims to verify the safety of a truly innovative drug.
We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of the LRKK2 gene and reduce the formation of alfasynuclein.